Depression of Tumor Necrosis Factor-a, Interleukin-6, and Interleukin-10 Production: A Reaction to the Initial Systemic Hyperactivation in Septic Shock

References

• Darville T, Giroir S, Jacobs R. The systemic inflammatory response syndrome (SIRS): Immunology and potential immunotherapy. Infection 1993; 21: 279–290
   PubMed Web of Science ®Google Scholar
• Goris R J. Multiple organ failure—whole body inflammation?. Schweiz Med Wochenschrift 1989; 119: 347
   PubMedGoogle Scholar
• Deitch E A. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992; 216: 117–134
   PubMed Web of Science ®Google Scholar
• Baue A E. Multiple, progressive, or sequential systems failure: A syndrome of the 1970′s. Arch Surg. 1975; 110: 779–789
   PubMedGoogle Scholar
• Bone R. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992; 101: 1644–1655, The APCC/SCCM Consensus Conference Committee
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Wolff S M. The role of interleukin-1 in disease. N Engl J Med. 1993; 328: 106–113
   PubMed Web of Science ®Google Scholar
• Glauser M P, Zanetti G, Baumgartner J D, Cohen J. Septic shock: Pathogenesis. Lancet. 1991; 338: 732–736
   PubMed Web of Science ®Google Scholar
• Dinarello C A, Gelfand J A, Wolff S M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269: 1829–1835
   PubMed Web of Science ®Google Scholar
• Fisher C J, Agosti J M, Opal S M, Lowry S F, Balk R A, Sadoff J C, Abraham E, Schein R MH, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996; 334: 1697–1702
   PubMed Web of Science ®Google Scholar
• Fisher C J, Dhainault J F, Opal S M. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836–1843
   PubMed Web of Science ®Google Scholar
• Heath A W. Cytokines and infection. Curr Opin Immunol. 1992; 213: 380–384
   Google Scholar
• Bone R C. The pathogenesis of sepsis. Ann Intern Med. 1991; 115: 457–469
   PubMed Web of Science ®Google Scholar
• Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest. 1991; 21: 559–573
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia—United States, 1979–1987. MMWR CDC Surveill Summ 1990; 39: 31–34
   PubMedGoogle Scholar
• Rackow E C, Astiz M E. The pathophysiology and treatment of septic shock. JAMA 1991; 266: 548–554
   PubMed Web of Science ®Google Scholar
• Munoz C, Carlet J, Fitting C, Misset B, Bleriot J P, Cavaillon J P. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991; 88: 1747–1754
   PubMed Web of Science ®Google Scholar
• Livingstone D H, Appel S H, Wellhausen S R, Sonnenfeld G, Polk H C. Depressed interferon-g production and monocyte HLA-DR expression after severe injury. Arch Surg. 1989; 123: 1309–1313
   Google Scholar
• Ertel W, Kremer J P, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg F W. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85: 1341–1347
   PubMed Web of Science ®Google Scholar
• Tracey K J, Cerami A. Tumor necrosis factor: An updated review of ist biology. Crit Care Med. 1993; 21: 415–422
   PubMed Web of Science ®Google Scholar
• De Waal Malefyt R, Yssel H, Roncarolo M G, Spits H, de Vries J E. Interleukin-10. Curr Opin Immunol. 1992; 4: 314–320
   PubMed Web of Science ®Google Scholar
• Andus T, Geiger T, Hirano X, Kishimoto X, Heinrich P C. Action of human recombinant interleukin-6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute phase proteins. Eur J Immunol. 1988; 181: 739–746
   Google Scholar
• Hack C E, De Groot E R, Felt-Bersma R JF. Increased plasma levels of IL-6 in sepsis. Blood 1989; 74: 1704–1710
   PubMed Web of Science ®Google Scholar
• Ayala A, Kisala J M, Felt J A, Perrin M M, Chaudry I H. Does endotoxin tolerance prevent the release of inflammatory monokines during sepsis?. Arch Surg 1992; 127: 191–196
   PubMedGoogle Scholar
• Ziegler-Heitbrock H WL. Molecular mechanism in tolerance to lipopolysaccharide. J Inflammation 1995; 45: 13–26
   PubMedGoogle Scholar
• Frankenberger M, Pechumer H, Ziegler-Heitbrock H WI. Interleukin 10 is upregulated in LPS-tolerance. J Inflammation 1995; 45: 56–63
   PubMedGoogle Scholar
• The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659–665
   PubMed Web of Science ®Google Scholar
• Sweet M J, Hume D A. Endotoxin signal transduction in macrophages. J Leukocyte Biol. 1996; 60: 8–26
   PubMed Web of Science ®Google Scholar
• Ertel W, Krombach F, Kremer J P, Jarrar D, Thiele V, Eymann J, Muenzing S, Faist E, Messmer K, Schildberg F W. Mechanisms of cytokine cascade activation in patients with sepsis: Normal cytokine transcription despite reduced CD14 receptor expression. Surgery 1993; 114: 243–251
   PubMedGoogle Scholar
• Cannon J G, Tompkins R G, Gelfand J A. Circulating interleu-kin-1 and tumor necrosis factor in septic shock and endotoxin fever. J Infect Dis. 1990; 161: 79–84
   PubMed Web of Science ®Google Scholar
• Calvano Serum, van der Poll X, Coyle S M, Barie B S, Moldawer L L, Lowry S F. Monocyte tumor necrosis factor recetor levels as a predictor of risk in human sepsis. Arch Surg. 1996; 131: 434–437
   PubMedGoogle Scholar
• Marchant A, Deviere J, Byl B, de Groote D, Vincent J L, Goldmann M. Interleukin-10 production during septicaemia. Lancet. 1994; 343: 707–708
   PubMed Web of Science ®Google Scholar